Phase I Trial of Intratumoral Administration of NIS Expressing Strain of Measles Virus in Unresectable or Recurrent Malignant Peripheral Nerve Sheath Tumor
Abstract
Study approved by Mayo IRB on April 18, 2016, and by USAMRMC/ORP/HRPO on May 6, 2016. All study staff completed IRB training. Dose volume charts have been developed to facilitate pharmacy orders. Study opened for enrollment on May 17, 2016. Study coordinators identified and assigned to the study by Mayo Clinic Cancer Center. One patient was identified as a possible study participant, but before enrollment she required hospitalization for pulmonary embolus. Due to treatment with anticoagulants, the patient was not eligible for participation. We are continuing study enrollment.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2016
- Accession Number
- AD1020694
Entities
People
- Dusica Babovic-vuksanovic